里昂研究报告指，3间内地药企包括中生制药(01177.HK) 、翰森制药(03692.HK) 及康哲药业(00867.HK) ，上半年均录得稳健业绩，2024年下半年及2025年上半年均实现双位数收入增长。该行预期势头将于2025年下半年延续，推动因素包括更多创新药物上市及新产品销售增加、内地医疗保险支出环境更有利、以及潜在的商业拓展(BD)收入。股份方面，该行重申对中生制药“跑赢大市”评级，...
Source Link里昂研究报告指，3间内地药企包括中生制药(01177.HK) 、翰森制药(03692.HK) 及康哲药业(00867.HK) ，上半年均录得稳健业绩，2024年下半年及2025年上半年均实现双位数收入增长。该行预期势头将于2025年下半年延续，推动因素包括更多创新药物上市及新产品销售增加、内地医疗保险支出环境更有利、以及潜在的商业拓展(BD)收入。股份方面，该行重申对中生制药“跑赢大市”评级，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.